The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML

Alan K Burnett, Nigel H Russell, Dominic Culligan, Jamie Cavanagh, Jonathan Kell, Keith Wheatley, Andra Virchis, Robert K Hills, Donald Milligan, AML Working Group of the UK National Cancer Research Institute

Research output: Contribution to journal › Article › peer-review

41 Citations (Scopus)

Fingerprint

Dive into the research topics of 'The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML'. Together they form a unique fingerprint.

Medicine & Life Sciences